
AstraZeneca taps two more targets from its AI partner, again in CKD and IPF
AstraZeneca is doubling down in chronic kidney disease and idiopathic pulmonary fibrosis by selecting one target for each of those via its AI-powered partner.
Originally teamed up in 2019, the Big Pharma has now selected a total of five targets via its UK counterpart, BenevolentAI. The tally includes two targets in CKD and three in IPF, a lung-scarring and breathing-constriction disease with two approved drugs — Boehringer Ingelheim’s Ofev and Roche’s Esbriet, both given the nod in 2014 — and a recent generic entry.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.